TRI-LUMA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRI-LUMA (TRI-LUMA).
Tri-Luma combines fluocinolone acetonide (corticosteroid), hydroquinone (melanocytotoxic agent), and tretinoin (retinoid). Fluocinolone reduces inflammation and melanocyte activity; hydroquinone inhibits tyrosinase, blocking melanin synthesis; tretinoin promotes epidermal turnover and enhances hydroquinone penetration.
| Metabolism | Fluocinolone acetonide is metabolized primarily in the liver via CYP3A4; hydroquinone undergoes conjugation (glucuronidation and sulfation) in the liver; tretinoin is metabolized by CYP450 enzymes (mainly CYP2C8, CYP2C9, and CYP3A4) and isomerized to isotretinoin. |
| Excretion | TRI-LUMA (fluocinolone acetonide, hydroquinone, tretinoin) is a topical combination; systemic absorption is minimal. The components are metabolized in the liver and excreted via urine (fluocinolone: ~70% renal, tretinoin: ~70% biliary/fecal, hydroquinone: ~80% renal as glucuronide conjugate). |
| Half-life | Fluocinolone acetonide: ~3.5 hours (topical); hydroquinone: ~4.8 hours (topical); tretinoin: ~1-2 hours (topical). Clinically, half-lives are short, allowing once-daily dosing. |
| Protein binding | Fluocinolone acetonide: ~90% bound to albumin and corticosteroid-binding globulin; hydroquinone: ~20% bound to albumin; tretinoin: >95% bound to albumin and lipoproteins. |
| Volume of Distribution | Due to minimal systemic absorption after topical application, Vd is not clinically meaningful; for reference, fluocinolone acetonide has a Vd of ~1.4 L/kg after IV administration. |
| Bioavailability | Topical: Systemic absorption is minimal (<5% for each component) due to low percutaneous penetration; not administered systemically. |
| Onset of Action | Topical: Effects on hyperpigmentation and acne may be noted within 2-4 weeks of consistent use. |
| Duration of Action | Topical: Duration of action is approximately 24 hours with once-daily application; clinical improvement is sustained with continued use. |
| Brand Substitutes | Lumaglo Forte Cream, Magnalyte Plus Cream, Lumacip Plus Cream |
Apply a thin layer to the face once daily at bedtime, covering the entire affected area.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustments are recommended; use with caution in severe renal impairment. |
| Liver impairment | No specific dose adjustments are recommended; use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established; use is not recommended. |
| Geriatric use | Clinical studies have not included sufficient numbers; use with caution due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TRI-LUMA (TRI-LUMA).
| Breastfeeding | Not known if hydroquinone or fluocinolone acetonide are excreted in human milk. Caution advised. No M/P ratio available. Avoid application to breast area to prevent infant ingestion. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, topical corticosteroids have shown teratogenicity; however, the risk from topical application is lower than systemic. Tri-Luma contains hydroquinone, which has limited data; fluocinolone acetonide is a corticosteroid. First trimester: avoid due to theoretical risk. Second and third trimesters: use only if potential benefit justifies risk to fetus. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any component, use in children under 12 years, use on broken or irritated skin, use during pregnancy (FDA Category C for tretinoin; avoid unless benefit outweighs risk), use while breastfeeding (hydroquinone may be excreted in breast milk, avoid use on large areas or for long duration).
| Precautions | Skin irritation, depigmentation, exogenous ochronosis with prolonged hydroquinone use, photosensitivity, potential for skin atrophy and telangiectasias from corticosteroid, avoid use in patients with history of melanoma or other skin cancers, avoid sun exposure, use with caution in dark-skinned individuals due to risk of hypopigmentation. |
Loading safety data…
| Fetal Monitoring | Monitor for maternal skin irritation, infection, or hypothalamic-pituitary-adrenal axis suppression with prolonged use. No specific fetal monitoring required unless topical corticosteroid used extensively on large areas, then consider monitoring for intrauterine growth restriction. |
| Fertility Effects | No known effects on fertility based on available data. Topical application minimizes systemic absorption, unlikely to impact reproductive function. |